文献速递头颈部肿瘤放疗姑息放疗与转移瘤

N3期鼻咽癌根治性放化疗后S-1维持化疗的疗效分析

Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma.
PubMed 文献 · Radiat Oncol · 2019-10-22

该回顾性研究纳入2014-2016年130例N3期鼻咽癌患者,比较根治性放化疗后联合S-1维持化疗(21例)与未联合维持化疗(109例)的疗效。中位随访41个月,维持化疗组3年总生存率和无远处转移生存率显著优于对照组,且毒性轻微可耐受。

要点

  • N3期鼻咽癌根治性放化疗后S-1维持化疗可显著改善3年总生存率(95.2% vs 76.3%,p=0.046)。
  • 维持化疗组3年无远处转移生存率亦显著提高(90.5% vs 70.3%,p=0.043),无局部区域失败生存率无显著差异。
  • S-1维持化疗常见毒性为1-2级皮肤色素沉着、白细胞减少、乏力、中性粒细胞减少、厌食和恶心,轻微可耐受。

核心结论

  • N3期鼻咽癌患者根治性放化疗后使用S-1维持化疗,生存优于未维持化疗患者,且毒性轻微可耐受。
  • 仍需进一步临床试验评估S-1维持化疗在N3期鼻咽癌患者中的疗效。

研究设计与样本

  • 回顾性研究,纳入2014-2016年所有接受根治性放化疗的N3期鼻咽癌患者,比较联合维持化疗(CRT-MC)与未联合维持化疗(CRT-non-MC)的队列。
  • 共纳入130例N3期患者,其中21例(16.2%)接受CRT-MC,109例(83.8%)接受CRT-non-MC。
  • 除新辅助化疗周期数外,两组患者特征无显著差异。
  • 放疗采用调强放疗(IMRT)。

主要发现

  • IMRT后69例达完全缓解(CR)(CRT-MC组10例,CRT-non-MC组59例),61例达部分缓解(PR)(11例 vs 50例),无稳定或进展病例。
  • 存活患者中位随访41个月,CRT-non-MC组与CRT-MC组3年总生存率分别为76.3%与95.2%(p=0.046)。
  • 3年无远处转移生存率分别为70.3%与90.5%(p=0.043)。
  • 3年无局部区域失败生存率分别为84.9%与100%(p=0.091),差异无统计学意义。
  • 维持化疗常见毒性为皮肤色素沉着、白细胞减少、乏力、中性粒细胞减少、厌食和恶心,均为1-2级,不严重。

关键数值与推荐

  • 3年总生存率:CRT-MC组95.2% vs CRT-non-MC组76.3%,p=0.046。
  • 3年无远处转移生存率:CRT-MC组90.5% vs CRT-non-MC组70.3%,p=0.043。
  • 3年无局部区域失败生存率:CRT-MC组100% vs CRT-non-MC组84.9%,p=0.091。
  • 维持化疗毒性均为1-2级。

临床怎么用

  • 对于N3期鼻咽癌患者,根治性放化疗后考虑使用S-1维持化疗可能改善生存,且毒性可耐受。
  • 需结合患者个体情况权衡维持化疗的获益与风险,目前证据来自回顾性研究,尚需前瞻性临床试验验证。

局限性

  • 回顾性研究设计,存在选择偏倚可能。
  • 维持化疗组样本量较小(21例)。
  • 两组新辅助化疗周期数存在显著差异。
  • 随访时间有限,中位随访41个月。
  • 需进一步临床试验评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with N3 stage nasopharyngeal carcinoma (NPC) are at high risk for treatment failure. This study aims to assess the efficacy of maintenance chemotherapy (MC) using S-1 (MC-S1), a novel oral fluoropyrimidine agent, following definitive chemoradiotherapy (CRT) using intensity-modulated radiotherapy (IMRT) in patients with N3 nasopharyngeal carcinoma (N3-NPC). METHODS: A retrospective review was conducted for all N3-NPC treated with CRT with MC (CRT-MC) or without MC (CRT-non-MC) during 2014-2016. Toxicities with MC were recorded. Overall survival (OS), locoregional failure-free survival (LFFS) and distant metastasis free survival (DMFS) were compared between CRT-MC vs. CRT-non-MC cohorts. RESULTS: A total of 130 N3 patients were identified, of whom 21 (16.2%) were treated with CRT-MC, and 109 (83.8%) with CRT-non-MC. Patient characteristics did not significantly differ between the CRT-MC and CRT-non-MC groups, with the exception of the number of cycles of neoadjuvant chemotherapy. Following IMRT 69 patients achieved a complete response (CR) (CRT-MC: 10; CRT-non-MC: 59), 61 had a partial response (PR) (11 vs. 50), and none maintained stable disease (SD) or developed progression of disease (PD). After a median follow-up of 41 months for surviving patients, a significant differences in OS (76.3% vs. 95.2%, p = 0.046) and DMFS (70.3% vs. 90.5%, p = 0.043) but not LFFS (84.9% vs. 100%, p = 0.091) at 3 years were observed between the CRT-non-MC and CRT-MC groups. Skin hyperpigmentation, leucopenia, fatigue, neutropenia, anorexia and nausea were the common but not severe (grade 1-2) toxicities of MC. CONCLUSIONS: Using MC-S1 in N3-NPC patients following IMRT achieved superior survival to the CRT-non-MC patients. The toxicities of MC-S1 were mild and tolerable. Further clinical trials are required to evaluate the efficacy of MC-S1 in N3-NPC patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Zong J, Xu H, Chen B, et al. Maintenance chemotherapy using S-1 following definitive chemoradiotherapy in patients with N3 nasopharyngeal carcinoma. Radiat Oncol. 2019. PMID: 31640719. doi:10.1186/s13014-019-1387-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。